Progresses of Fluoroquinolone and Tetracycline in the Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children

Abstract

Macrolides are the first-line antibiotics for the treatment of Mycoplasma pneumoniae pneumonia. Resistance to macrolides is one of the main causes of refractory Mycoplasma pneumoniae pneumonia. In recent years, the resistance of macrolides has increased rapidly, especially in Asia, which produces great difficulties for clinical treatment. Fluoroquinolones and tetracyclines have shown benefits in shortening the duration of symptoms of Mycoplasma pneumoniae pneumonia. However, for the safety of second-line drugs in children, clinicians should balance the risks and benefits when choosing treatment options. This article will review the efficacy and safety of fluoroquinolone and tetracycline in the treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.